BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 915 filers reported holding BAXTER INTL INC in Q4 2013. The put-call ratio across all filers is 0.90 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2015 | $9,305,000 | -70.9% | 135,836 | -68.8% | 0.10% | -72.1% |
| Q4 2014 | $31,948,000 | +15.5% | 435,907 | +13.1% | 0.34% | -12.4% |
| Q3 2014 | $27,651,000 | +261.5% | 385,266 | +264.2% | 0.39% | +262.6% |
| Q2 2014 | $7,648,000 | -21.8% | 105,786 | -20.4% | 0.11% | -24.6% |
| Q1 2014 | $9,774,000 | +16.6% | 132,840 | +10.2% | 0.14% | -1.4% |
| Q4 2013 | $8,381,000 | +1.8% | 120,508 | -3.8% | 0.14% | -5.9% |
| Q3 2013 | $8,231,000 | -7.2% | 125,299 | -2.1% | 0.15% | -13.1% |
| Q2 2013 | $8,867,000 | – | 128,008 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |